United Kingdom Daily Briefing

The Hormuz reopening paradox is playing out live on the FTSE 100: lower oil prices help the broader UK economy but directly cut revenues for BP and BHP, whose combined index weighting means a sustained commodity sell-off translates into FTSE 100 underperformance versus global peers. BP at $39.10 is sitting near a technical support level; a close below $38 would open the door to the mid-$30s on an oil-price-driven earnings-cut narrative. Mining peer BHP faces the same arithmetic from iron ore: the Hormuz normalization competes with China demand uncertainty for which story wins the commodity macro trade this month.

GSK's 2.8% decline to $50.69 follows PFE -2.7% and JNJ -2.5% in the US, confirming that the healthcare rotation is a global factor move, not company-specific news. When semiconductor names surge on AI momentum, the capital has to exit defensive healthcare across all geographies. For GSK specifically, the question is whether the selloff extends to AstraZeneca (AZN) at tomorrow's open — AZN has been a relative outperformer in UK pharma on oncology pipeline strength, so its ability to hold levels would be a crucial signal for FTSE sector breadth.

BlackRock's disclosure that 75% of IBIT investors were new to the ETF wrapper is a structural signal about crypto's demand profile: it's not just existing ETF investors rotating into Bitcoin exposure, it's a new buyer cohort. For UK-based investors, this has implications for how the FCA might frame further crypto-product approvals, and for Hargreaves Lansdown and AJ Bell as platforms that may face demand pressure to offer crypto ETF access on their ISA-eligible platforms. The 75% new-to-ETF data also suggests Bitcoin ETF flows are additive to existing equity ETF demand, not cannibalistic.